Atopic Dermatitis Clinical Trial
Official title:
Skin Integrity After Newborns' First Bath And Development of Eczema and Allergy at 2 Years
Atopic dermatitis (AD) is a chronic allergic skin disease with onset in early childhood and
increasing prevalence in Westernized countries. Current well newborn guidelines for washing
babies with soap were adopted by U.S. hospitals in the 1970s, before the rise in prevalence
of allergic disease and AD (also called eczema). Increased transepidermal water-loss (TEWL)
in newborn skin at 2 days of life was recently identified as a predictor of AD and allergy
development by age 2 years. Risk for AD in babies was also linked to decreased skin
colonization with certain skin microflora, such as staphylococcal organisms. Together, these
data raise the question of whether newborn skincare guidelines have the potential to modify
a baby's risk for allergy development. Our current practice of washing babies with soap may
alter TEWL or other natural factors in skin that protect babies from development of AD and
allergy. More knowledge is needed about the impact of infant skincare practices on allergy
development.
The objective of this pilot study is to determine the impact of a baby's first bath on
his/her transepidermal water loss (TEWL) and skin microflora. Study procedures will include
collection of TEWL measurements and skin swabs for skin microflora analysis pre/post first
bath in healthy term newborns at UVA. This data will serve as preliminary data for future
studies.
The UVA study team will perform all study-related procedures and will collect all data.
Contact information and permission for the study team to contact the subject's family will
be obtained at enrollment.
Pre-bath Procedures: Prior to the first bath, a study team member will:
1. Record health information about the subject.
2. Record the amount of vernix covering the subject's skin.
3. Measure skin TEWL (see TEWL below).
4. Procure skin swabs for microflora analysis (see Skin swabs below)
Post-bath Procedures: Following the subject's first bath, a study team member will repeat
pre-bath procedures.
TEWL Procedure TEWL measurement will be performed using the Tewameter - a non-invasive,
wand-like instrument that sits atop skin like a stethoscope and measures the water
evaporating from the skin. TEWL is a validated non-invasive procedure for assessment of
newborn skin integrity.
Skin Swabs Skin swabs, softer than Q-tips, will be wiped across the skin with soft pressure
to allow transfer of the baby's skin microflora onto the swab for analysis of
skin-colonizing microorganisms, according to established methods.
AD and allergy development by 2 years The medical charts of enrolled subjects will be
reviewed at 24 months of life to determine the incidence of any physician-diagnosis of AD or
allergic disease. Subjects who have no physician-diagnosis of AD or allergy in their medical
record will be contacted according to the contact information they provided at enrollment.
Investigators will get a medical release signed with informed consent so the study team can
contact the PCP of the subject if they are not followed at UVA.
None of these procedures are part of routine care in newborns. All procedures are being done
solely for research purposes and pose minimal risk to subjects.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05018806 -
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04090229 -
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
|
Phase 1 | |
Terminated |
NCT03847389 -
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05388760 -
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
|
Phase 2 | |
Completed |
NCT05530707 -
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
|
N/A | |
Completed |
NCT02595073 -
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
|
Phase 3 | |
Recruiting |
NCT05509023 -
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
|
Phase 2 | |
Recruiting |
NCT05048056 -
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04598269 -
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT03936335 -
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
|
||
Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
Recruiting |
NCT05029895 -
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
|
||
Terminated |
NCT03654755 -
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04556461 -
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
|
Phase 2 | |
Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
Completed |
NCT03719742 -
A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer
|
N/A | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Completed |
NCT03441568 -
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
|
N/A | |
Recruiting |
NCT06366932 -
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
|
Phase 4 | |
Completed |
NCT03304470 -
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
|
Phase 2 |